
Jorge Santos da Silva, MoonLake Immunotherapeutics CEO (via website)
MoonLake's CEO on its looming mid-year pivotal readout in skin disease
MIAMI — MoonLake Immunotherapeutics is expected to have one of the biotech industry’s biggest stock-moving clinical readouts around the middle of this year for a pair …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.